FLUMIST QUADRIVALENT
Total Payments
$6.5M
Transactions
7,063
Doctors
5,390
Companies
3
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $106,412 | 3,247 | 2,904 |
| 2023 | $1.1M | 3,387 | 2,978 |
| 2022 | $114,750 | 1 | 0 |
| 2021 | $2.3M | 405 | 372 |
| 2020 | $2.6M | 7 | 3 |
| 2019 | $281,742 | 16 | 12 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Royalty or License | $5.9M | 9 | 90.5% |
| Unspecified | $419,446 | 6 | 6.5% |
| Food and Beverage | $148,078 | 7,010 | 2.3% |
| Consulting Fee | $31,423 | 25 | 0.5% |
| Space rental or facility fees (teaching hospital only) | $16,500 | 12 | 0.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $774.54 | 1 | 0.0% |
Payments by Type
General
$6.1M
7,057 transactions
Research
$419,446
6 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 4 Randomized, Double-Blind, Placebo-controlled Study to Evaluate the Safety of 1 New | AstraZeneca Pharmaceuticals LP | $280,440 | 0 |
| FLUMIST QUADRIVALENT | AstraZeneca Pharmaceuticals LP | $138,006 | 0 |
| MEDI3250-1116 Phase 4 Post Marketing Commitment Effectiveness | AstraZeneca Pharmaceuticals LP | $1,000 | 0 |
Top Doctors Receiving Payments for FLUMIST QUADRIVALENT
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Iowa City, IA | $6.3M | 30 |
| , MD | Pediatric Infectious Diseases | Aurora, CO | $5,773 | 4 |
| , M.D | Pediatrics | Chicago, IL | $5,442 | 7 |
| , M.D | Family Medicine | Jenkintown, PA | $3,222 | 3 |
| Janet Englund | Pediatric Infectious Diseases | Seattle, WA | $2,400 | 3 |
| , MD, PHD | Hospitalist | Nashville, TN | $2,048 | 1 |
| , MD | Pediatric Infectious Diseases | Jackson, MS | $2,048 | 1 |
| , DO | Pediatrics | Tulsa, OK | $1,913 | 1 |
| , MD | Pediatrics | Houston, TX | $1,820 | 1 |
| , MD | Pediatric Infectious Diseases | Houston, TX | $1,600 | 1 |
| , M.D | Pediatrics | Brooklyn Park, MN | $1,530 | 1 |
| David Nelson | Pediatrics | Washington, DC | $1,360 | 1 |
| , M.D | Pediatrics | New Bern, NC | $523.12 | 2 |
| , DO | Family Medicine | Centerville, OH | $246.58 | 2 |
| , D.O | Rheumatology | Loxahatchee, FL | $187.45 | 3 |
| , D.O | Internal Medicine | Cincinnati, OH | $170.40 | 2 |
| , FNP-C | Family | San Antonio, TX | $153.28 | 1 |
| , D.O | Internal Medicine | Metairie, LA | $148.56 | 1 |
| , MD | Pediatrics | Walnut Creek, CA | $146.72 | 7 |
| , MD | Pediatrics | Gainesville, FL | $143.34 | 5 |
| , MD | Pediatrics | Gainesville, FL | $143.33 | 5 |
| , MD | Pediatrics | Gainesville, FL | $143.33 | 5 |
| , APRN | Nurse Practitioner | Gainesville, FL | $143.33 | 5 |
| , M.D | Pediatrics | Hackensack, NJ | $142.05 | 7 |
| , MD | Adolescent Medicine | Hackensack, NJ | $142.05 | 7 |
Ad
Manufacturing Companies
- AstraZeneca Pharmaceuticals LP $6.5M
- AstraZeneca UK Limited $30,646
- Acerta Pharma LLC $226.54
Product Information
- Type Drug
- Total Payments $6.5M
- Total Doctors 5,390
- Transactions 7,063
About FLUMIST QUADRIVALENT
FLUMIST QUADRIVALENT is a drug associated with $6.5M in payments to 5,390 healthcare providers, recorded across 7,063 transactions in the CMS Open Payments database. The primary manufacturer is AstraZeneca Pharmaceuticals LP.
Payment data is available from 2019 to 2024. In 2024, $106,412 was paid across 3,247 transactions to 2,904 doctors.
The most common payment nature for FLUMIST QUADRIVALENT is "Royalty or License" ($5.9M, 90.5% of total).
FLUMIST QUADRIVALENT is associated with 3 research studies, including "A Phase 4 Randomized, Double-Blind, Placebo-controlled Study to Evaluate the Safety of 1 New" ($280,440).